Biogen and UCB may have a differentiated treatment for systemic lupus erythematosus (SLE) based on detailed results from the first Phase III clinical trial of the anti-CD40L antibody dapirolizumab pegol, which consistently separated from placebo with efficacy improving over time across multiple endpoints, including reduced disease activity, less frequent lupus flares and decreased steroid use.
Key Takeaways
- Biogen and UCB were slated to present detailed positive Phase III PHOENYCS GO results for dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) as a...
The companies reported topline results from the 321-patient Phase III PHOENYCS GO trial in September and plan to initiate a second Phase III study, named PHOENYCS FLY, before the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?